New DNA booster shot targets omicron in small trial

NCT ID NCT06436911

Completed ⭐️ VACCINE ⭐️ Sponsor: Entos Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1/2 trial tested a new DNA booster vaccine called Covigenix VAX-002 in 46 healthy adults aged 18 and older. The vaccine is designed to protect against newer COVID-19 variants like Omicron. Participants had already received a primary COVID-19 vaccine or booster at least 3 months before. The study checked for safety and immune response at different doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Covigenix VAX-002 (plasmid DNA vaccine)
What this could lead to: If successful, this could provide a safe and effective booster option targeting new COVID-19 variants like Omicron.
What could go wrong: This is an early-phase trial with only 46 participants, so results may not apply to larger populations. The vaccine is still experimental and may not provide strong or lasting protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Centricity Research

Burlington, Ontario, L7M4Y1, Canada
Centricity Research

Toronto, Ontario, M4G3E8, Canada
Centricity Research

Toronto, Ontario, M9W4L6, Canada
Diex Recherche

Sherbrooke, Quebec, J1L0H8, Canada
Diex Recherche Quebec

Québec, Quebec, G1V4T3, Canada
University of Alberta

Edmonton, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.